ABBISKO-B (02256) announced that its novel selective CDK4 inhibitor ABSK192 monotherapy and combination therapy preclinical research results were presented at the 2026 ENA Conference
ABBISKO-B (02256) announced that its subsidiary, Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Therapeutics), announced that the preclinical research results of its independently developed novel selective CDK4 inhibitor ABSK192 were presented in poster format at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2026 (2026 ENA Conference).
ABBISKO-B (02256) announced that its subsidiary Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Therapeutics) announced that the preclinical research results of its independently developed novel selective CDK4 inhibitor ABSK192 were presented in poster form at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2026 (2026 ENA Conference). This study was selected for the Late-Breaking Abstracts (LBA) program, and Dr. Zhang Nannan, Senior Director of Translational Medicine and Biomarker Research at Abbisko Therapeutics, presented on-site the monotherapy activity and broad combination therapy potential of ABSK192 in HR+/HER2- breast cancer models.
Related Articles

SA SA INT'L (00178) will pay an interim dividend of HK$0.04 per share on December 18.

SSY GROUP (02005): Low-calcium Peritoneal Dialysis Solution (Bicarbonate G1.5%) and Other Drugs Obtain Drug Production Registration Approval

SA SA INT'L (00178) announces interim results, profit attributable to shareholders HK$170 million, up 239.14% year-on-year; sales performance in core markets Hong Kong and Macau improved significantly.
SA SA INT'L (00178) will pay an interim dividend of HK$0.04 per share on December 18.

SSY GROUP (02005): Low-calcium Peritoneal Dialysis Solution (Bicarbonate G1.5%) and Other Drugs Obtain Drug Production Registration Approval

SA SA INT'L (00178) announces interim results, profit attributable to shareholders HK$170 million, up 239.14% year-on-year; sales performance in core markets Hong Kong and Macau improved significantly.






